about
The role of concentration-effect relationships in the assessment of QTc interval prolongationModeling disease progression in acute stroke using clinical assessment scales.Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.Tips and traps analyzing pediatric PK data.Sepsis progression and outcome: a dynamical model.The simcyp population based simulator: architecture, implementation, and quality assurance.Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children.Application of a mechanism-based disease systems model for osteoporosis to clinical data.Clinical pharmacology = disease progression + drug actionDisease modification in migraine: a concept that has come of age?Coping with time scales in disease systems analysis: application to bone remodelingBayesian quantitative disease-drug-trial models for Parkinson's disease to guide early drug development.Comparing the efficacy of NSAIDs and paracetamol in children.Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis.Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.A hemodynamic model to guide blood pressure control during deliberate hypotension with sodium nitroprusside in children.Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.Hypertabastic survival model.Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria.Population pharmacokinetic and pharmacodynamic modelling of the effects of nicorandil in the treatment of acute heart failure.A time to event tutorial for pharmacometricians.Modeling NSCLC progression: recent advances and opportunities availableModeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats.Mechanism-based disease progression modeling of type 2 diabetes in Goto-Kakizaki ratsDose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditionsEndpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease.Multiscale modeling in drug discovery and development: future opportunities and present challenges.Diverse approaches for the enhancement of oral drug bioavailability.Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal.The current role of model-based drug development.Disease progression and neuroscience.Population pharmacometrics in support of analgesics studies.A conceptual review on systems biology in health and diseases: from biological networks to modern therapeutics.Considerations when using pharmacokinetic/pharmacodynamic modeling to determine the effectiveness of simple analgesics in children.Development of a pharmacokinetic/pharmacodynamic/disease progression model in NC/Nga mice for development of novel anti-atopic dermatitis drugs.Whither pharmacometrics?: present state and future choices.A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.
P2860
Q26866417-731E1C79-CCAB-4883-83BE-AE4D1A1B0C34Q30497328-FD186871-76B6-44BB-88F3-51A85B8A9309Q33524423-BB7149E2-2E1E-4A93-A4CE-CC58EED32775Q33820152-AE8A87CC-0847-496F-B8C5-588DCB5309AFQ34496641-B78B58FA-BB24-4D22-A499-21F3F6A619EBQ34502721-63AEA940-E464-49A6-B8A0-760380C108DAQ34533270-6E7E1211-8D2C-4DA9-BCC2-3E8E6EDABEBFQ34546981-5231CCC1-8035-45E6-8666-6BB9357523DBQ34953659-5463F2E4-74F5-4EFD-B8AD-FC862B2314F7Q35056865-CCE3BEA8-606D-44FF-8847-72ED4B6CDCE2Q35591581-2F8788CD-923E-4C2E-B102-417EBD9DB48DQ35595794-95503385-4F63-4D2E-899D-D364C4D0A986Q35680419-F60F91FE-86EB-4D43-A68D-30CB4629C5BBQ35801353-3C7A7D15-5711-4A91-B760-C102F7DCE959Q35846713-722479F0-9769-4BC7-9F17-48EC17AE7F30Q35894569-A9205247-B620-49A9-A8CD-DB3B40D8C5EAQ36090728-9FC3DB1E-63CB-44B6-8991-102C6008A354Q36316063-28D0E0DF-E051-4424-A033-B824987125EFQ36505504-47BCAA07-A874-49CA-B32C-99D3280CBB9DQ36853534-1441AC80-13C0-43C2-8DB8-EB9719124664Q36907009-965C8403-0508-4AF6-A025-3889D600D52AQ36910615-2C94CD78-015B-422F-812A-9877528F743AQ36952913-782A5609-1139-4B37-8F1A-27FB7938DE23Q37055749-C4E04A26-8810-4B11-B32F-CBC912A62CE3Q37343974-4A43826E-D615-4384-85BD-E9DBF64D3076Q37353460-36C00AA0-03C4-4567-A924-9FAB82591EC0Q37378042-264606A0-9E7E-4A8D-9ECE-D33496907653Q37762442-25357519-030C-4E95-BD02-BFE233BC1B56Q37863645-76371FF9-9604-4D86-BD0C-D1197ECE9489Q37886138-563B026E-914B-456E-AFE0-49E169F75EB4Q37891050-FCDFA076-9783-4F71-B6F8-AA8026AD418CQ38028538-2547635D-1A39-4CB7-8D58-1F00088DF5ABQ38099584-7D704AD5-DE1E-4603-8D27-4D4A70C45583Q38175171-E82CFBAF-1E78-455C-8E15-C9FD21C063C7Q38193097-FD43C86D-F8D6-4E1B-8283-60DD720D8CD3Q38544082-FCE262F5-1957-4E53-BCFB-A6130A43BC52Q38990396-E1BC18CA-D212-4D79-B661-81D2F005C319Q39189602-604AD94D-F4AB-4CD2-A75A-9F1BF0AF341CQ39602527-70CAC7D7-28E2-4F74-ABC7-2B830F4AF27CQ39639283-E570B6CB-38B5-4118-BAA9-D994B88C724A
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Drug treatment effects on disease progression.
@ast
Drug treatment effects on disease progression.
@en
Drug treatment effects on disease progression.
@nl
type
label
Drug treatment effects on disease progression.
@ast
Drug treatment effects on disease progression.
@en
Drug treatment effects on disease progression.
@nl
prefLabel
Drug treatment effects on disease progression.
@ast
Drug treatment effects on disease progression.
@en
Drug treatment effects on disease progression.
@nl
P1476
Drug treatment effects on disease progression
@en
P2093
P304
P356
10.1146/ANNUREV.PHARMTOX.41.1.625
P50
P577
2001-01-01T00:00:00Z